{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:52:27Z","timestamp":1791532347613,"version":"4.3.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,12]]},"abstract":"<jats:p>Induction chemotherapy (IC) prior to concurrent chemo-radiotherapy is the recommended treatment for unresectable stage III non-small cell lung cancer (NSCLC). However, the optimum number of IC cycles for improved survival outcomes is still not known. Here, we assessed the efficacy of 2 or more cycles of IC for unresectable stage III NSCLC patients from our hospital. Data on unresectable stage III NSCLC patients treated with IC + concurrent chemo-radiotherapy at our hospital between 2018 and 2022 were retrieved and analyzed, and survival outcomes compared between IC = 2 and IC &gt; 2 patients. Univariate and multivariate Cox regression, and Chi-square or Fisher exact test were used to assess prognosis and acute toxicity profiles. One hundred twenty-six patients were recruited; 90 for IC = 2 and 36 for IC &gt; 2. Median follow-up time was 26 months [IQR 16-38]. Three-year overall survival was not statistically significant between the 2 groups (77.8% vs 75.0%, <jats:italic toggle=\"yes\">P<\/jats:italic> = .453). Distant metastasis free survival, loco-regional recurrence free survival and progression free survival were also not significant, (90.0% vs 86.1%, <jats:italic toggle=\"yes\">P<\/jats:italic> = .068), 97.8% vs 97.2%, <jats:italic toggle=\"yes\">P<\/jats:italic> = .056), and (73.3% vs 66.7%, <jats:italic toggle=\"yes\">P<\/jats:italic> = .446) respectively. Univariate and multivariate Cox regression analysis revealed smoking, T_stage, N_stage, and IC_regimen as independent prognostic factor for overall survival, while drinking and T_stage were risk factors for progression free survival. In summary, 2 cycles of platinum-based IC was effective for stage III unresectable NSCLC and adding more than 2 cycles did not offer extra survival benefits.<\/jats:p>","DOI":"10.1097\/md.0000000000033760","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:11:33Z","timestamp":1683900693000},"page":"e33760","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Optimum cycles of induction chemotherapy in concurrent chemo-radiotherapy management of unresectable stage III non-small cell lung cancer: Results from a single institutional database"],"prefix":"10.1097","volume":"102","author":[{"given":"Mohamed Bassirou Moukeila","family":"Yacouba","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohui","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Zhongnan Hospital of Wuhan University, and Clinical Cancer Study Center of Hubei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Thokerunga","sequence":"additional","affiliation":[{"name":"Program and Department of Clinical Laboratory Medicine, Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Cedric","family":"Bongolo","sequence":"additional","affiliation":[{"name":"Program and Department of Clinical Laboratory Medicine, Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamou Foumakoye","family":"Gado","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care, H\u00f4pital G\u00e9n\u00e9ral DE R\u00e9f\u00e9rence Niamey, Republic of Niger."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjuan","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3023-8875","authenticated-orcid":false,"given":"Zongze","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China.","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-3-319-24223-1_10","article-title":"Chemotherapy resistance in lung cancer.","volume":"893","author":"Kim","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"100462","DOI":"10.1016\/j.ctarc.2021.100462","article-title":"Treatment patterns in non-small-cell lung cancer in China: results from the cancer MPact survey 2020.","volume":"29","author":"Durbin","year":"2021","journal-title":"Cancer Treatment Res Commun"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1097\/01.JTO.0000283093.09465.20","article-title":"A1-04: sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs).","volume":"2","author":"Rolland","year":"2007","journal-title":"J Thor Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.2014.59.2360","article-title":"Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American society of clinical oncology clinical practice guideline endorsement of the American society for radiation oncology evidence-based clinical practice guideline.","volume":"33","author":"Bezjak","year":"2015","journal-title":"J Clin Oncol"},{"key":"R6-20250504","first-page":"CD002140","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer.","author":"Rowell","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2017.11.135","article-title":"The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non\u2013small cell lung cancer.","volume":"13","author":"Miller","year":"2018","journal-title":"J Thor Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"v64","DOI":"10.1093\/annonc\/mdj953","article-title":"First line chemotherapy in advanced or metastatic NSCLC.","volume":"17 Suppl 5","author":"Rinaldi","year":"2006","journal-title":"Ann Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1310\/hpj4807-550","article-title":"Docetaxel and cisplatin regimen for non-small-cell lung cancer.","volume":"48","author":"Yang","year":"2013","journal-title":"Hosp Pharm"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III Non\u2013small-cell lung cancer: ASCO guideline.","volume":"40","author":"Daly","year":"2022","journal-title":"J Clin Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e16167e16167","DOI":"10.1097\/MD.0000000000016167","article-title":"Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: a meta-analysis and systematic review.","volume":"98","author":"Hung","year":"2019","journal-title":"Medicine (Baltim)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e6165e6165","DOI":"10.1097\/MD.0000000000006165","article-title":"The effect of induction chemotherapy in patients with locally advanced non-small cell lung cancer who received chemoradiotherapy: a systematic review and meta-analysis.","volume":"96","author":"Luo","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00000421-200206000-00007","article-title":"A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.","volume":"25","author":"Kim","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.785022","article-title":"One cycle of concurrent chemotherapy vs. two cycles of concurrent chemotherapy with radiation therapy in patients with limited-stage small cell lung cancer.","volume":"11","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1533033820951802","DOI":"10.1177\/1533033820951802","article-title":"Radiotherapy dose and induction chemotherapy cycles are associated with prognosis and toxicity risk: a retrospective study of 227 patients with unresectable stage III non-small-cell lung cancer.","volume":"19","author":"Chen","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.oraloncology.2016.10.014","article-title":"Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: a propensity scores matching analysis.","volume":"62","author":"Peng","year":"2016","journal-title":"Oral Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00405-022-07794-w","article-title":"Determination of optimum number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a single-center retrospective study.","volume":"280","author":"Ahmed","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/hed.26141","article-title":"Optimizing number of cycles of induction chemotherapy for patients with nasopharyngeal carcinoma: retrospective survival analysis.","volume":"42","author":"He","year":"2020","journal-title":"Head Neck"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1002\/cam4.5256","article-title":"Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response.","volume":"12","author":"Jiang","year":"2023","journal-title":"Cancer Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/028418699432266","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.","volume":"38","author":"Tan","year":"1999","journal-title":"Acta Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"100452","DOI":"10.1016\/j.lanwpc.2022.100452","article-title":"Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB\/IV non-small cell lung cancer in China (2015\u20132017): a multicenter prospective study.","volume":"23","author":"Shi","year":"2022","journal-title":"Lancet Regional Health West Pac"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cllc.2011.03.030","article-title":"Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.","volume":"12","author":"Aydiner","year":"2011","journal-title":"Clin Lung Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:25:10Z","timestamp":1746325510000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":23,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033760","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}